Skip to main content
. 2019 Mar 23;3(2):268–276. doi: 10.1002/rth2.12192

Figure 1.

Figure 1

Trial design and pharmacokinetic sampling. Doses of each trial product were separated by at least 21 d; each dose administration was preceded by a 96‐h washout from non‐modified FIX products. FIX, factor IX; PK, pharmacokinetic; rFIXFc, recombinant factor IX‐Fc fusion protein; V, visit